Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: A phase I/II pharmacokinetic interaction study

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1111-1118

  Flaherty, Keith T ^a,d   Lathia, Chetan ^b   Frye, Reginald F ^c   Schuchter, Lynn ^a   Redlinger, Maryann ^a   Rosen, Mark ^a   O'dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BAYER CORPORATION   (United States)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

^d NONE   (United States)

Author keywords

Cytochrome P450; Dextromethorphan; Midazolam; Omeprazole; Probe substrate cocktail; Sorafenib

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DEXTRORPHAN; MIDAZOLAM; OMEPRAZOLE; SORAFENIB;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MELANOMA; PANCREATITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; STEADY STATE;

EID: 82455192303     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1585-0     Document Type: Article

References (39)

1. SM Wilhelm C Carter L Tang D Wilkie A McNabola H Rong C Chen X Zhang P Vincent M McHugh Y Cao J Shujath S Gawlak D Eveleigh B Rowley L Liu L Adnane M Lynch D Auclair I Taylor R Gedrich A Voznesensky B Riedl LE Post G Bollag PA Trail 2004 BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 7099 7109 15466206 10.1158/0008-5472.CAN-04-1443 1:CAS:528:DC%2BD2cXotFalsbk%3D (Pubitemid 39331023)
2. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai F Rolland T Demkow TE Hutson M Gore S Freeman B Schwartz M Shan R Simantov RM Bukowski 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 125 134 17215530 10.1056/NEJMoa060655 1:CAS:528:DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
3. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, Poulin-Costello M, Moscovici M, Voliotis D, Bruix J, Group FtSIS (2007) Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial) [abstract]. J Clin Oncol ASCO Annual Meeting Proceedings Part I. (June 20 Suppl) 25: LBA1
4. I Duran SJ Hotte H Hirte EX Chen M MacLean S Turner L Duan GR Pond C Lathia S Walsh JJ Wright J Dancey LL Siu 2007 Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors Clin Cancer Res 13 4849 4857 17699864 10.1158/1078-0432.CCR-07-0382 1:CAS:528: DC%2BD2sXptVGmt7c%3D (Pubitemid 47294792)
5. K Mross S Steinbild F Baas D Gmehling M Radtke D Voliotis E Brendel O Christensen C Unger 2007 Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib Eur J Cancer 43 55 63 17095207 10.1016/j.ejca.2006.08.032 1:CAS:528:DC%2BD2sXmtVemtA%3D%3D (Pubitemid 46054474)
6. H Richly BF Henning P Kupsch K Passarge M Grubert RA Hilger O Christensen E Brendel B Schwartz M Ludwig C Flashar R Voigtmann ME Scheulen S Seeber D Strumberg 2006 Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors Ann Oncol 17 866 873 16500908 10.1093/annonc/mdl017 1:STN:280:DC%2BD283jtVKksw%3D%3D
7. LL Siu A Awada CH Takimoto M Piccart B Schwartz T Giannaris C Lathia O Petrenciuc MJ Moore 2006 Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer Clin Cancer Res 12 144 151 16397036 10.1158/1078-0432.CCR-05-1571 1:CAS:528: DC%2BD28Xht1Gmuw%3D%3D (Pubitemid 43166188)
8. P Kupsch BF Henning K Passarge H Richly K Wiesemann RA Hilger ME Scheulen O Christensen E Brendel B Schwartz E Hofstra R Voigtmann S Seeber D Strumberg 2005 Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer Clin Colorectal Cancer 5 188 196 16197622 10.3816/CCC.2005.n.030
9. CW Ryan BH Goldman PN Lara Jr PC Mack TM Beer CM Tangen D Lemmon CX Pan HA Drabkin ED Crawford 2007 Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group J Clin Oncol 25 3296 3301 17664477 10.1200/JCO.2007.11.1047 1:CAS:528:DC%2BD2sXhtVWqs7jO (Pubitemid 47325615)
10. JA Gollob WK Rathmell TM Richmond CB Marino EK Miller G Grigson C Watkins L Gu BL Peterson JJ Wright 2007 Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer J Clin Oncol 25 3288 3295 17664476 10.1200/JCO.2007.10.8613 1:CAS:528:DC%2BD2sXhtVWqs7jM (Pubitemid 47325614)
11. B Escudier N Lassau E Angevin JC Soria L Chami M Lamuraglia E Zafarana V Landreau B Schwartz E Brendel JP Armand C Robert 2007 Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma Clin Cancer Res 13 1801 1809 17363536 10.1158/1078-0432.CCR-06-1432 1:CAS:528:DC%2BD2sXivV2gtLo%3D (Pubitemid 46952949)
12. AA Adjei JR Molina SJ Mandrekar R Marks JR Reid G Croghan LJ Hanson JR Jett C Xia C Lathia R Simantov 2007 Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer Clin Cancer Res 13 2684 2691 17473200 10.1158/1078-0432.CCR-06-2889 1:CAS:528:DC%2BD2sXkslOhur4%3D (Pubitemid 46788036)
13. C Gridelli A Rossi F Mongillo M Bareschino P Maione F Ciardiello 2007 A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics Clin Lung Cancer 8 396 398 17562243 10.3816/CLC.2007.n.023 (Pubitemid 46918286)
14. DF McDermott JA Sosman R Gonzalez FS Hodi GP Linette J Richards JW Jakub M Beeram S Tarantolo S Agarwala G Frenette I Puzanov L Cranmer K Lewis J Kirkwood JM White C Xia K Patel E Hersh 2008 Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group J Clin Oncol 26 2178 2185 18445842 10.1200/JCO.2007.14.8288 1:CAS:528:DC%2BD1cXms1OrtLY%3D
15. Agarwala SS, Keilholz U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Patel K, Hauschild A (2007) Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J Clin Oncol ASCO Annual Meeting Proceedings Part I. (June 20 Supplement) 25:8510
16. C Lathia J Lettieri F Cihon M Gallentine M Radtke P Sundaresan 2006 Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 57 685 692 16133532 10.1007/s00280-005-0068-6 1:CAS:528:DC%2BD28Xjs1KktLk%3D
17. Bayer HealthCare Pharmaceuticals Inc (2009) Nexavar® (Sorafenib) Prescribing Information. http://www.nexavar.com/html/download/Nexavar-PI.pdf. Accessed 19 March, 2010
18. D Strumberg JW Clark A Awada MJ Moore H Richly A Hendlisz HW Hirte JP Eder HJ Lenz B Schwartz 2007 Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 426 437 17470685 10.1634/theoncologist.12-4-426 1:CAS:528:DC%2BD2sXmtlSitrs%3D (Pubitemid 46698720)
19. Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol. 2009 Oct; 20(10):2269-76. (Epub 2009 Aug 20)
20. Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events (CTCAE) v3.0. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm. Accessed: 22 March, 2010
21. ML Veronese W Sun B Giantonio J Berlin J Shults L Davis DG Haller PJ O'Dwyer 2005 A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer Br J Cancer 92 1846 1849 15870719 10.1038/sj.bjc.6602569 1:CAS:528:DC%2BD2MXkt1Sgsr4%3D (Pubitemid 40826131)
22. RS Midgley DJ Kerr KT Flaherty JP Stevenson SE Pratap KM Koch DA Smith M Versola RA Fleming C Ward PJ O'Dwyer MR Middleton 2007 A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan Ann Oncol 18 2025 2029 17846021 10.1093/annonc/mdm366 1:STN:280:DC%2BD2sjktFeqtw%3D%3D (Pubitemid 350286244)
23. WA Messersmith DA Laheru NN Senzer RC Donehower P Grouleff T Rogers SK Kelley DA Ramies BL Lum M Hidalgo 2004 Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities Clin Cancer Res 10 6522 6527 15475439 10.1158/1078-0432.CCR-04-0746 1:CAS:528:DC%2BD2cXot1Oiur8%3D (Pubitemid 39346546)
24. KE Thummel DD Shen TD Podoll KL Kunze WF Trager CE Bacchi CL Marsh JP McVicar DM Barr JD Perkins, et al. 1994 Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation J Pharmacol Exp Ther 271 557 566 7965756 1:CAS:528:DyaK2MXhvVyqu7Y%3D (Pubitemid 24333174)
25. M Chang G Tybring ML Dahl E Gotharson M Sagar R Seensalu L Bertilsson 1995 Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19 Br J Clin Pharmacol 39 511 518 7669487 1:CAS:528:DyaK2MXmt1Ogtro%3D
26. P Dayer T Leemann R Striberni 1989 Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity Clin Pharmacol Ther 45 34 40 2910636 10.1038/clpt.1989.6 1:CAS:528:DyaL1MXosl2mtw%3D%3D (Pubitemid 19047144)
27. M Chang ML Dahl G Tybring E Gotharson L Bertilsson 1995 Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype Pharmacogenetics 5 358 363 8747407 10.1097/00008571-199512000-00004 1:CAS:528:DyaK28XhtFyitrc%3D (Pubitemid 26011441)
28. DS Streetman JF Bleakley JS Kim AN Nafziger JS Leeder A Gaedigk R Gotschall GL Kearns JS Bertino Jr 2000 Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail" Clin Pharmacol Ther 68 375 383 11061577 10.1067/mcp.2000.109519 1:CAS:528:DC%2BD3cXot1Wjsbc%3D
29. M Wong RL Balleine M Collins C Liddle CL Clarke H Gurney 2004 CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy Clin Pharmacol Ther 75 529 538 15179407 10.1016/j.clpt.2004.02.005 1:CAS:528:DC%2BD2cXkslWmt78%3D (Pubitemid 38746603)
30. ER Lepper SD Baker M Permenter N Ries RH van Schaik PW Schenk DK Price D Ahn NF Smith G Cusatis RG Ingersoll SE Bates RH Mathijssen J Verweij WD Figg A Sparreboom 2005 Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients Clin Cancer Res 11 7398 7404 16243813 10.1158/1078-0432.CCR-05-0520 1:CAS:528:DC%2BD2MXhtFartbvM (Pubitemid 41507700)
31. Y Bottiger 2006 Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 Eur J Clin Pharmacol 62 621 625 16791583 10.1007/s00228-006- 0156-5 (Pubitemid 44127990)
32. HM Gonzalez EM Romero AA Peregrina de JCT E Escobar-Islas F Lozano C Hoyo-Vadillo 2003 CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans J Clin Pharmacol 43 1211 1215 14551175 10.1177/0091270003258170 1:CAS:528:DC%2BD3sXptFKitbg%3D (Pubitemid 37280792)
33. C Funck-Brentano PY Boelle C Verstuyft C Bornert L Becquemont JM Poirier 2005 Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects Eur J Clin Pharmacol 61 821 829 16315033 10.1007/s00228-005-0051-5 1:CAS:528:DC%2BD2MXht1Gqu7zP (Pubitemid 41720270)
34. TD Bjornsson JT Callaghan HJ Einolf V Fischer L Gan S Grimm J Kao SP King G Miwa L Ni G Kumar J McLeod RS Obach S Roberts A Roe A Shah F Snikeris JT Sullivan D Tweedie JM Vega J Walsh SA Wrighton 2003 The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective Drug Metab Dispos 31 815 832 12814957 10.1124/dmd.31.7.815 1:CAS:528:DC%2BD3sXltFalu70%3D (Pubitemid 36759050)
35. Takeda Pharmaceuticals America Inc (2009) ACTOS® Prescribing Information. http://www.actos.com/actospro/prescribinginfo.aspx. Accessed:19 March, 2009
36. R Yuan DA Flockhart JD Balian 1999 Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam J Clin Pharmacol 39 1109 1125 10579141 1:CAS:528: DC%2BD3cXivFWlsg%3D%3D (Pubitemid 30644013)
37. RF Yeh VE Gaver KB Patterson NL Rezk F Baxter-Meheux MJ Blake JJ Eron Jr CE Klein JC Rublein AD Kashuba 2006 Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers J Acquir Immune Defic Syndr 42 52 60 16639344 1:CAS:528:DC%2BD28XlsFGqtrY%3D (Pubitemid 43947946)
38. KP Kanebratt U Diczfalusy T Backstrom E Sparve E Bredberg Y Bottiger TB Andersson L Bertilsson 2008 Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4beta-hydroxycholesterol Clin Pharmacol Ther 84 589 594 18650803 10.1038/clpt.2008.132 1:CAS:528:DC%2BD1cXht1OisLrL
39. S Borges L Li MA Hamman DR Jones SD Hall JC Gorski 2005 Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance Drug Metab Dispos 33 1052 1055 15821042 10.1124/dmd.104.003459 1:CAS:528:DC%2BD2MXlslWqsb4%3D (Pubitemid 41002788)